Press release
Radiopharmaceutical Theranostics Market Size is Expected to expand at a CAGR of 15.1% by 2031 |Transparency Market Research
Radiopharmaceutical Theranostics market is estimated to attain a valuation of US$ 12.4 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 15.1% during the forecast period, 2023-2031
Get a Sample Copy of the Radiopharmaceutical Theranostics Market Research Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82604&utm_source=openpr_amitugare&utm_medium=openpr
The significant players operating in the global Radiopharmaceutical Theranostics market are
Advanced Accelerator Applications (Novartis AG), Aurobindo Pharma, Bayer AG, Blue Earth Diagnostics (Bracco), Cardinal Health, Clarity Pharmaceuticals, GE Healthcare, Jubliant Radiopharma, Navidea Biopharmaceuticals, Inc., SOFIE, Telix Pharmeceuticals, and Lantheus Medical Imaging
Key Drivers of the Radiopharmaceutical Theranostics Market:
Growing Incidence of Cancer: The increasing incidence of cancer globally, along with the demand for more effective and personalized treatment options, drives the adoption of radiopharmaceutical theranostics. Targeted radionuclide therapies offer the potential to selectively deliver radiation to cancer cells while sparing healthy tissues, leading to improved therapeutic outcomes and reduced side effects.
Advancements in Molecular Imaging: Technological advancements in molecular imaging techniques, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging modalities (PET/CT, PET/MRI), enable precise localization and characterization of tumors. Radiopharmaceutical-based imaging agents facilitate early detection, accurate staging, and treatment planning in oncology and other disease areas.
Personalized Medicine Approaches: The shift towards personalized medicine approaches, including molecular profiling, genetic testing, and companion diagnostics, drives the demand for targeted therapies and theranostic agents. Radiopharmaceutical theranostics allows for individualized treatment strategies based on tumor biology, receptor expression patterns, and patient-specific factors.
Clinical Evidence and Regulatory Approvals: The accumulation of clinical evidence supporting the efficacy and safety of radiopharmaceutical theranostics, along with regulatory approvals for new radiopharmaceuticals and indications, accelerates market adoption. Clinical trials demonstrate the benefits of theranostic approaches in improving patient outcomes, prolonging survival, and enhancing quality of life for cancer patients.
Recent Developments in the Radiopharmaceutical Theranostics Market:
Introduction of novel radiopharmaceuticals targeting specific biomarkers and molecular pathways implicated in cancer progression, metastasis, and treatment resistance, offering opportunities for personalized and targeted therapy in oncology.
Development and commercialization of companion diagnostic tests and imaging agents for patient selection, treatment response monitoring, and disease surveillance in theranostic applications, facilitating precision medicine approaches in clinical practice.
Integration of artificial intelligence (AI), machine learning (ML), and image analysis algorithms into radiopharmaceutical theranostics workflows to enhance diagnostic accuracy, treatment planning, and prognostic prediction in oncology and other disease areas.
Expansion of theranostic applications beyond oncology to include neurology, cardiology, endocrinology, and infectious diseases, driven by advances in molecular imaging, radiopharmaceutical chemistry, and disease-specific biomarkers.
Adoption of hybrid imaging platforms, advanced radiochemistry facilities, and cyclotron production capabilities in healthcare institutions and radiopharmaceutical manufacturing facilities to support theranostic research, production, and clinical translation.
Buy this Premium Research Report: - https://www.transparencymarketresearch.com/checkout.php?rep_id=82604<ype=S
Market Segmentation -
Segmentation
Radioisotope
Technetium-99
Gallium-68
Iodine-131
Radium-223
Fluorine-18
Yttrium-90
Lutetium-177
Copper-67 & 64
Samarium-153
Others
Application
Oncology
Cardiology
Others
Source
Nuclear Reactors
Cyclotrons
Approach
Targeted Therapeutic (Rx)
Companion Diagnostic (DX)
Radiotracer Type
Peptidic
Non-peptidic
End-user
Hospitals
Academic & Research Institutes
Others
This Report lets you identify the opportunities in Radiopharmaceutical Theranostics Market by means of a region:
North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)
Key Features of the Radiopharmaceutical Theranostics Market Report: -
➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.
➤ Examine the market opportunities for stakeholders by identifying higher growth sections.
➤ To study and analyze the global Radiopharmaceutical Theranostics industry status and forecast including key regions.
➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.
➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.
➤ It helps you make strategic business decisions and investment plans.
More Trending Reports by Transparency Market Research -
Plasma Fractionation Market: https://www.globenewswire.com/en/news-release/2024/03/06/2841356/32656/en/Plasma-Fractionation-Market-to-reach-USD-42-6-billion-by-2031-Expanding-at-a-CAGR-of-6-7-Transparency-Market-Research-Inc.html
Stretcher Chair Market: https://www.globenewswire.com/en/news-release/2024/03/06/2841462/32656/en/Stretcher-Chair-Market-Projected-to-Reach-USD-403-2-million-by-2031-Growing-at-a-CAGR-of-4-2-Transparency-Market-Research-Inc.html
About Us Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Radiopharmaceutical Theranostics Market Size is Expected to expand at a CAGR of 15.1% by 2031 |Transparency Market Research here
News-ID: 3435721 • Views: …
More Releases from Transparency Market Research
Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive A …
The global Neuromorphic Chip Market is entering a defining phase of exponential growth, propelled by a surge in artificial intelligence (AI) applications, edge computing expansion, and rapid advancements in next-generation semiconductor technologies. According to the latest industry analysis, the market-valued at US$ 56.2 Mn in 2023-is projected to expand at an extraordinary CAGR of 40.1% from 2024 to 2034, reaching an estimated US$ 2.3 Bn by 2034.
Examine key highlights and…
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological …
The global Neuroprotection Market continues to gain unprecedented momentum as healthcare systems worldwide intensify their focus on combating neurological disorders. With a valuation of US$ 31.6 Bn in 2022, the market is on track to reach US$ 60.1 Bn by 2031, expanding at a robust 7.5% CAGR during the forecast period. The rise in dementia, stroke, Parkinson's, epilepsy, and multiple sclerosis-combined with aging demographics and a surge in sedentary lifestyles-has…
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Inn …
The global neuroregeneration therapy market continues to chart steady, sustained growth. The increasing incidence of neurological disorders-including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, stroke, diabetic neuropathy, and spinal cord injuries-is significantly influencing market expansion. In 2023, the market was worth US$ 37.0 Bn, demonstrating rising demand for treatments capable of repairing or regenerating damaged neural tissue.
Examine key highlights and takeaways from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86322
With breakthroughs…
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Adv …
The global neuroscience market stood at US$ 30.1 Bn in 2022, reflecting the significant technological and clinical potential of neurological research. Projected to grow at a CAGR of 3.7% from 2023 to 2031, the industry is expected to reach US$ 41.6 Bn by 2031. Rising prevalence of neurodegenerative diseases, advancements in neuroimaging, integration of artificial intelligence, and the emergence of brain-computer interfaces are shaping the next decade of neuroscience innovation.
Examine…
More Releases for Radiopharma
Nuclear Pharmacy Market Future Business Opportunities 2025-2032 | Curium Pharma, …
The Latest study titled Nuclear Pharmacy Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report…
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and St …
Actinium's Chief Medical Officer, said, "In addition to demonstrating unprecedented 100% access to BMT in Iomab-B treated patients with active r/r AML and achieving the primary endpoint of dCR with high statistical significance, we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial. We look forward to returning to EBMT and once again highlighting the positive results from the Phase 3 SIERRA trial…
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma A …
Biotech Stocks Taking Centerstage
As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate…
2030 Projections: Radiopharmaceutical Synthesizers Market to Deliver Dynamic Pro …
The Radiopharmaceutical Synthesizers Market Research Report 2023-2030 provides in-depth information on market trends, market capacity, industry size, growth factors, share, innovations, competitive environment, business problems, and more. This report's historical data confirms demand growth on a global, national, and regional scale. The studies on the global industry cover everything from comprehensive research to market size and forecasting to dynamics, growth factors, prospects, and hazards, as well as vendor knowledge. The…
Automated Radiosynthesis Modules Market Strategic Assessment & SWOT Analysis 202 …
An Informative report titled as Global Automated Radiosynthesis Modules Market has recently been published by Report Consultant to its online repository. This statistical data offers an in-depth analysis by considering several segments, such as type, size, technology and applications. Different exploratory techniques such as, qualitative and quantitative analysis have been used to give data accurately. For better understanding of the customers, it uses effective graphical presentation techniques, such as graphs,…
Cyclotron Market Growth Opportunities Analysis Report | GE Healthcare, Siemens H …
Cyclotron Market: Introduction
According to the report, the global cyclotron market was valued at US$ 215.5 Mn in 2019. It is projected to expand at a CAGR of ~3% from 2020 to 2030. Expansion activities of key radiopharma players; applications in clinical trials; increase in the geriatric population; pipeline assessment of new drugs; and disease indication mortality are major factors driving the cyclotron market. The shutdown of a few nuclear reactors has led to the…
